Local Tolerability After Lip Filler Injections
Conditions
Keywords
lip, fillers, Hyaluronic acid
Brief summary
The purpose of this study is to demonstrate the efficacy and safety of Emervel Lips and Juvederm Ultra smile
Interventions
DEVICEEmervel Lips
Lip treatment of both upper and lower lip
DEVICEJuvederm Ultra Smile
Lip treatment of both upper and lower lip
Sponsors
Galderma R&D
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subjects aged 18 to 65 years. * Subjects with the intention to undergo lip augmentation treatment. * Subjects treatment-naïve for lip augmentation treatment * Subjects with lip appearance judged by the treating investigator to be suitable for lip line treatment * Subjects with signed informed consent.
Exclusion criteria
* Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation (e.g. aspirin or other nonsteroidal anti-inflammatory drugs \[NSAIDs\]), Omega-3 or vitamin E within 10 days before study treatment, or a history of bleeding disorders. * Prior surgery or tattoo to the upper or lower lip or lip line. * Presence of any abnormal lip structure, such as a scar or lump or severe lip asymmetry. * Previous tissue augmenting therapy in the lip area (including oral commissures, marionette and perioral lines) with HA or collagen filler, or laser treatment, within 12 months before study entry. * Permanent implant or treatment with non-HA or non-collagen filler in the area surrounding the lips (including nasolabial folds, oral commissures, marionette and perioral lines). * History of herpes labialis with an outbreak within 4 weeks of study entry or with 4 or more outbreaks in the 12 months before study entry. * Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or on the area to be treated. * History of angioedema. * Previous hypersensitivity to HA. * Previous hypersensitivity to lidocaine or other amide-type anaesthetics * Cancerous or precancerous lesions in the area to be treated. * Immunosuppressive therapy, chemotherapy, treatment with biologics or systemic corticosteroids within 3 months before study treatment. * Pregnancy or breast feeding. * Participation in any other clinical study within 30 days before inclusion. * Other condition preventing the subject to entering the study in the investigator's opinion, e.g. subjects not likely to avoid other facial cosmetic treatments below the level of the lower orbital rim, subjects anticipated to be unreliable or incapable of understanding the study assessment or unrealistic expectations of treatment result. * Study staff or close relative to study staff (e.g. parents, children, siblings or spouse).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local tolerability | 14 days | To assess local tolerability after treatment including erythema, bruising, itching, swelling, pain/ tenderness at 14 days. Number of subjects reporting the events will be analysed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AE reporting | 24 weeks | To evaluate long-term safety throughout the study period |
| Global Aesthetic Improvement Scale (GAIS) | Week 2 to week 24 | To evaluate esthetic change of lips from baseline using GEIS |
| Lip Fullness Grading Scale (LFGS) | 0-24 weeks | To evaluate esthetic change of lips from baseline using LFGS |
| Subject's satisfaction | 0-24 weeks | To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire |
Countries
Germany
Outcome results
None listed